-+ 0.00%
-+ 0.00%
-+ 0.00%

Immutep Wins US Patent for Efti Combination Therapies

PUBT·11/10/2026 23:49:06
Listen to the news
Immutep Wins US Patent for Efti Combination Therapies
  • Immutep received a new US patent for efti-based combination therapies, bringing its US patent portfolio in this family to five.
  • The patent covers preparations combining eftilagimod alfa with PD-1 pathway inhibitors, extending protection for its cancer immunotherapy combinations.
  • Protection expires March 23, 2038, including an 806-day patent term adjustment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.